 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
5 October 1999 | Volume 131 Issue 7 | Pages 522-530
The stiff-person syndrome, a rare and disabling disorder, is characterized by muscle rigidity and episodic spasms that involve axial and limb musculature. Continuous contraction of agonist and antagonist muscles caused by involuntary motor-unit firing at rest are the hallmark clinical and electrophysiologic signs of the disease. Except for global muscle stiffness, results of neurologic examination are usually normal. Results of conventional computed tomography and magnetic resonance imaging of the brain are also normal.
The cause of the stiff-person syndrome is unknown; however, an autoimmune pathogenesis is suspected because of 1) the presence of antibodies against glutamic acid decarboxylase (GAD), the rate-limiting enzyme for the synthesis of the inhibitory neurotransmitter
The stiff-person syndrome is clinically elusive but potentially treatable and should be considered in patients with unexplained stiffness and spasms. Drugs that enhance GABA neurotransmission, such as diazepam, vigabatrin, and baclofen, provide mild to modest relief of clinical symptoms. Immunomodulatory agents, such as steroids, plasmapheresis, and intravenous immunoglobulin, seem to offer substantial improvement. Results of an ongoing controlled trial will elucidate the role of these agents in the treatment of the disease.
Author and Article Information
From the National Institutes of Health, Bethesda, Maryland.
An edited summary of a Clinical Staff Conference held on 28 October 1998 at the National Institutes of Health in Bethesda, Maryland.
Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of the reference:
Floeter MK. Inhibitory pathways defined by electrophysiology. In: Levy LM, moderator. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of
Acknowledgments: The authors thank major collaborators, including Drs. Mavis Fujii, David Jacobowitz, Mian Li, Sherry Thomas-Vorbach, Joan Kyhos, and Beverly McElroy. They also thank Dr. Mark Hallett for his support and Dr. Giovanni Di Chiro for setting up the new spectroscopy program at the National Institutes of Health.
Requests for Reprints: Lucien M. Levy, MD, PhD, Neuroimaging Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Room 5N226, Bethesda, MD 20892; e-mail, levy{at}codon.nih.gov. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Levy: National Institutes of Health, Building 10, Room 5N226, Bethesda, MD 20892.
Dr. Dalakas: National Institutes of Health, Building 10, Room 4N248, Bethesda, MD 20892.
Dr. Floeter: National Institutes of Health, Building 10, Room 5C101, Bethesda, MD 20892. NIH CONFERENCE
The Stiff-Person Syndrome: An Autoimmune Disorder Affecting Neurotransmission of
-Aminobutyric Acid
-aminobutyric acid [GABA]; 2) the association of the disease with other autoimmune conditions; 3) the presence of various autoantibodies; and 4) a strong immunogenetic association. Anti-GAD antibodies, which are found in high titers in most patients, seem to be directed against conformational forms of GAD. New evidence suggests that these antibodies may be pathogenic because they interfere with the synthesis of GABA. In addition, a reduction in brain levels of GABA, which is prominent in the motor cortex, has been demonstrated with magnetic resonance spectroscopy in patients with the stiff-person syndrome.
-aminobutyric acid. Ann Intern Med. 1999;131:523-524.
This article has been cited by other articles:
|
|
 |
|
  B. B. Murinson and J. B. Guarnaccia Stiff-person syndrome with amphiphysin antibodies: Distinctive features of a rare disease Neurology, December 9, 2008; 71(24): 1955 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M Gurcan and A R. Ahmed Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders Ann. Pharmacother., May 1, 2007; 41(5): 812 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Raju, G. Rakocevic, Z. Chen, G. Hoehn, C. Semino-Mora, W. Shi, R. Olsen, and M. C. Dalakas Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome Brain, December 1, 2006; 129(12): 3270 - 3276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rakocevic, R. Raju, C. Semino-Mora, and M. C. Dalakas Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology, September 26, 2006; 67(6): 1068 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Raju, J. Foote, J. P. Banga, T. R. Hall, C. J. Padoa, M. C. Dalakas, E. Ortqvist, and C. S. Hampe Analysis of GAD65 Autoantibodies in Stiff-Person Syndrome Patients J. Immunol., December 1, 2005; 175(11): 7755 - 7762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Levy, I. Levy-Reis, M. Fujii, and M. C. Dalakas Brain {gamma}-Aminobutyric Acid Changes in Stiff-Person Syndrome Arch Neurol, June 1, 2005; 62(6): 970 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Khasani, K Becker, and H-M Meinck Hyperekplexia and stiff-man syndrome: abnormal brainstem reflexes suggest a physiological relationship J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1265 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rakocevic, R. Raju, and M. C. Dalakas Anti-Glutamic Acid Decarboxylase Antibodies in the Serum and Cerebrospinal Fluid of Patients With Stiff-Person Syndrome: Correlation With Clinical Severity Arch Neurol, June 1, 2004; 61(6): 902 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Goeb, F Dubreuil, P Cabre, G Jean-Baptiste, and S Arfi Letter to the Editor Lupus, March 1, 2004; 13(3): 215 - 215. [PDF]
|
|
|
|
 |
|
 J. Bouw, K. Leendertse, M. A. J. Tijssen, and M. Dzoljic Stiff Person Syndrome and Anesthesia: Case Report Anesth. Analg., August 1, 2003; 97(2): 486 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Molloy, M. C. Dalakas, and M. K. Floeter Increased brainstem excitability in stiff-person syndrome Neurology, August 13, 2002; 59(3): 449 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Dalakas, M. Fujii, M. Li, B. Lutfi, J. Kyhos, and B. McElroy High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome N. Engl. J. Med., December 27, 2001; 345(26): 1870 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Dalakas, M. Li, M. Fujii, and D. M. Jacobowitz Stiff person syndrome: Quantification, specificity, and intrathecal synthesis of GAD65 antibodies Neurology, September 11, 2001; 57(5): 780 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Murinson and M. Rizzo Improvement of stiff-person syndrome with tiagabine Neurology, July 24, 2001; 57(2): 366 - 366. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Dalakas, M. Fujii, M. Li, and B. McElroy The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome Neurology, November 28, 2000; 55(10): 1531 - 1535. [Abstract] [Full Text] [PDF]
|
|
Article
